hydrogen has been researched along with Sclerosis, Systemic in 4 studies
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.
dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lactulose hydrogen breath test (LHBT) was evaluated in 21 patients suspected of having small intestinal bacterial overgrowth syndrome and 10 healthy volunteers as control." | 3.69 | [Lactulose hydrogen breath test in small intestinal bacterial overgrowth]. ( Bei, L; Pan, G; Wang, J, 1995) |
| "We found no relationship between gastroesophageal reflux, age of patients, duration of disease, and Raynaud's phenomenon." | 1.31 | Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. ( Frosch, M; Ganser, G; Hülskamp, G; Roth, J; Weber, P; Zimmer, KP, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Bei, L | 1 |
| Pan, G | 1 |
| Carola, F | 1 |
| Bianchi, PA | 1 |
| Basilisco, G | 1 |
| Weber, P | 1 |
| Ganser, G | 1 |
| Frosch, M | 1 |
| Roth, J | 1 |
| Hülskamp, G | 1 |
| Zimmer, KP | 1 |
| Soudah, HC | 1 |
| Hasler, WL | 1 |
| Owyang, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing[NCT01324895] | 944 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| A Pilot Study to Evaluate Safety and Effectiveness of Lanreotide in the Treatment of Patients With Small Bowel Motility Disorders (SBMD): a Prospective, Non-randomized, Single-center Study of 20 Participants[NCT03012594] | Phase 2 | 12 participants (Actual) | Interventional | 2017-05-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Improvement in symptoms assessed by improvement in Patient Assessment of Gastrointestinal Disorders Symptom Severity Index(PAGI-SYM) scores. If the PAGI-Sym scores were decreased by at least 0.7 points at 3 months when compared to baseline/pre treatment, then it will be considered that Lanreotide has significantly improved the symptom severity. Higher values represent worse symptoms.~The participant rated each of the measured gastrointestinal symptom severity as described 0=No symptom, 1=Very Mild Symptom, 2= Mild Symptoms, 3= Moderate symptom, 4=Severe symptom, 5= Very Severe symptom.~PAGI-SYM is a brief (20-items with 6 sub scales) symptom severity questionnaire that captures information on common upper gastrointestinal symptoms which include including Heartburn/regurgitation, Nausea/vomiting, Fullness/early satiety, bloating, Upper abdominal pain, and Lower abdominal pain. The presented data is an average of each sub scale." (NCT03012594)
Timeframe: 3 months
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Heartburn/regurgitation | Nausea/vomiting | Fullness/early satiety | Bloating | Upper abdominal pain | Lower abdominal pain | |
| Lanreotide | 1.48 | 1.00 | 2.36 | 2.43 | 2.14 | 2.00 |
If the small bowel transit time, as measured by wireless capsule endoscopy, is decreased to < 6hrs, then patient would be considered a responder and that lanreotide is efficacious. (NCT03012594)
Timeframe: 3 months
| Intervention | minutes (Mean) | ||||
|---|---|---|---|---|---|
| Gastric emptying time | Small bowel transit time | Colonic transit time | Small bowel and Colonic transit time | Whole gut transit time | |
| Lanreotide | 371.52 | 392 | 4767 | 5159 | 5530 |
4 other studies available for hydrogen and Sclerosis, Systemic
| Article | Year |
|---|---|
[Lactulose hydrogen breath test in small intestinal bacterial overgrowth].
Topics: Adult; Bacteria, Anaerobic; Breath Tests; Female; Humans; Hydrogen; Intestine, Small; Lactulose; Mal | 1995 |
Intraesophageal pH monitoring during acid infusion in patients with systemic sclerosis.
Topics: Acids; Adult; Aged; Esophagus; Female; Humans; Hydrogen; Hydrogen-Ion Concentration; Male; Middle Ag | 1999 |
Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease.
Topics: Adolescent; Child; Child, Preschool; Esophagus; Female; Gastroesophageal Reflux; Humans; Hydrogen; H | 2000 |
Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.
Topics: Adult; Aged; Breath Tests; Duodenum; Female; Gastrointestinal Motility; Humans; Hydrogen; Intestine, | 1991 |
Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.
Topics: Adult; Aged; Breath Tests; Duodenum; Female; Gastrointestinal Motility; Humans; Hydrogen; Intestine, | 1991 |
Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.
Topics: Adult; Aged; Breath Tests; Duodenum; Female; Gastrointestinal Motility; Humans; Hydrogen; Intestine, | 1991 |
Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.
Topics: Adult; Aged; Breath Tests; Duodenum; Female; Gastrointestinal Motility; Humans; Hydrogen; Intestine, | 1991 |